Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 3
2012 9
2013 8
2014 5
2015 8
2016 10
2017 13
2018 14
2019 6
2020 15
2021 17
2022 38
2023 36
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
The following terms were ignored: "", OR
Quoted phrases not found in phrase index: "937272-79-2"
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Review.
Drug therapy in MF is currently palliative and targets anemia, splenomegaly, and constitutional symptoms. JAK2 INHIBITORS: Ruxolitinib, fedratinib, and pacritinib are FDA approved and respectfully utilized in patients failing treatment with hydroxyurea, ruxolitinib, or wit …
Drug therapy in MF is currently palliative and targets anemia, splenomegaly, and constitutional symptoms. JAK2 INHIBITORS: Ruxolitinib, fedr …
Myelofibrosis.
Passamonti F, Mora B. Passamonti F, et al. Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. Blood. 2023. PMID: 36416738 Free PMC article. Review.
Standard treatment consists of anemia-oriented therapies, hydroxyurea, and JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib. Overall, spleen volume reduction of 35% or greater at week 24 can be achieved by 42% of ruxolitinib-, 47% of fedratinib-, 19% of pa …
Standard treatment consists of anemia-oriented therapies, hydroxyurea, and JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib. Fedratinib induces robust spleen responses, and …
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to indu …
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2023 Jan;187:106552. doi: 10.1016/j.phrs.2022.106552. Epub 2022 Nov 17. Pharmacol Res. 2023. PMID: 36403719 Free article. Review.
The following three drugs received FDA approval in 2022 for the treatment of these specified diseases: abrocitinib (atopic dermatitis), futibatinib (cholangiocarcinomas), pacritinib (myelofibrosis). All of the FDA-approved drugs are orally effective with the exception of n …
The following three drugs received FDA approval in 2022 for the treatment of these specified diseases: abrocitinib (atopic dermatitis), futi …
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT. ...Clinical improvement in hemoglobin and reduction in transfusion …
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pacriti …
A Comprehensive Overview of Globally Approved JAK Inhibitors.
Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. Shawky AM, et al. Pharmaceutics. 2022 May 6;14(5):1001. doi: 10.3390/pharmaceutics14051001. Pharmaceutics. 2022. PMID: 35631587 Free PMC article. Review.
These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. ...
These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, to …
Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S. Passamonti F, et al. Crit Rev Oncol Hematol. 2022 Dec;180:103862. doi: 10.1016/j.critrevonc.2022.103862. Epub 2022 Nov 1. Crit Rev Oncol Hematol. 2022. PMID: 36332787 Free article. Review.
This review summarizes current and emerging treatments for anemia in MF, including luspatercept and KER-050 (transforming growth factor-beta ligand traps), momelotinib and pacritinib (JAK inhibitors), pelabresib (a bromodomain extra-terminal domain inhibitor), PRM-151 (an …
This review summarizes current and emerging treatments for anemia in MF, including luspatercept and KER-050 (transforming growth factor-beta …
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Mesa RA, et al. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. Lancet Haematol. 2017. PMID: 28336242 Free PMC article. Clinical Trial.
We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. ...At week 24, the primary endpoint of SVR of 35% or more was achieved by 42 (19%) patients in the pacritinib g …
We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of …
Pacritinib: First Approval.
Lamb YN. Lamb YN. Drugs. 2022 May;82(7):831-838. doi: 10.1007/s40265-022-01718-y. Drugs. 2022. PMID: 35567653 Review.
Pacritinib (VONJO) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of myelofibrosis and graft-versus-host disease. ...The accelerated approval was based on results from the randomized, active-controlled, phase I …
Pacritinib (VONJO) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of m …
Pacritinib.
[No authors listed] [No authors listed] 2022 Jul 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Jul 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 35877951 Free Books & Documents. Review.
No information is available on the use of pacritinib during breastfeeding. The manufacturer recommends that breastfeeding be withheld during therapy and for 2 weeks after the last dose. ...
No information is available on the use of pacritinib during breastfeeding. The manufacturer recommends that breastfeeding be withheld …
178 results